Literature DB >> 9017347

The costs of non-insulin-dependent diabetes mellitus.

K G Alberti.   

Abstract

Entities:  

Mesh:

Year:  1997        PMID: 9017347     DOI: 10.1002/(SICI)1096-9136(199701)14:1<7::AID-DIA321>3.0.CO;2-3

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


× No keyword cloud information.
  6 in total

Review 1.  Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components.

Authors:  Girardin Jean-Louis; Ferdinand Zizi; Luther T Clark; Clinton D Brown; Samy I McFarlane
Journal:  J Clin Sleep Med       Date:  2008-06-15       Impact factor: 4.062

Review 2.  Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.

Authors:  R H Foster; G L Plosker
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

3.  More than measurement: practice team experiences of screening for type 2 diabetes.

Authors:  Jonathan Graffy; Julie Grant; Kate Williams; Simon Cohn; Sara Macbay; Simon Griffin; Ann Louise Kinmonth
Journal:  Fam Pract       Date:  2010-04-19       Impact factor: 2.267

Review 4.  The economics of screening and treatment in type 2 diabetes mellitus.

Authors:  Maria Raikou; Alistair McGuire
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 5.  Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.

Authors:  Adilson Guilherme; Joseph V Virbasius; Vishwajeet Puri; Michael P Czech
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

Review 6.  Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy.

Authors:  Alan J Garber
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.